

Please write legibly. All fields need to be completed in English.
Any missing information may cause a delay in the turnaround time of the test.

Patient Information		Treating Physician Information	
Given Name	Last/Family Name	Given Name	Last/Family Name
Sex at Birth	Date of Birth (DD/MM/YYYY)	Hospital/Clinic	
<input type="checkbox"/> Male <input type="checkbox"/> Female		Address	
Address		Postal Code	Country
Postal Code	Country	Telephone	Practicing Licence No.
Diagnosis (please indicate specifically)	Patient ID (NRIC/Passport No.)	Prefer e-Report? <input type="checkbox"/> Yes	
Stage	Primary Site	Email Required: _____	
Clinical History (attached notes separately if needed)			

Pathology & Specimen Information		
Submitting Staff Name	Institution/Hospital	<input type="checkbox"/> Same as above
Address (if different)	Postal Code	Country
Telephone	Email	
Date of Specimen Collection (DD/MM/YYYY)	Specimen site	Specimen ID
Is this a <input type="checkbox"/> RELAPSE case? Attach previous report (if any)	Previous lab accession no. (if any): _____	

Test Panel Selection* (tick where appropriate)			
Tissue Biopsy	<input type="checkbox"/> Essential Combined 50 DNA + Fusion genes	<input type="checkbox"/> DNA 68 68 DNA genes <input type="checkbox"/> Include Essential Fusion + 18 RNA genes	<input type="checkbox"/> Extended 109 DNA genes <input type="checkbox"/> Include Essential Fusion + 18 RNA genes
	<input type="checkbox"/> Essential DNA 45 genes		<input type="checkbox"/> Comprehensive 523 DNA + Fusion genes <input type="checkbox"/> Include HRD for Ovarian cancer only
	<input type="checkbox"/> Essential Fusion 18 RNA genes		<input type="checkbox"/> Comprehensive Fusion 501 RNA genes

Supplementary Tests	
Immunohistochemical (IHC)	<input type="checkbox"/> PD-L1 (SP263) <input type="checkbox"/> ALK <input type="checkbox"/> ROS1 <input type="checkbox"/> MMR (MLH, PMS2, MSH2, MSH6)
Other Tests	
Promoter Methylation	<input type="checkbox"/> MLH1 <input type="checkbox"/> MGMT
*Refer to reverse for tissue specimen guidelines & requirements. Full list of genes available upon request.	

Physician's Declaration & Confirmation of Informed Consent		
I declare that the information provided is accurate and true to the best of my knowledge at the time of submission. My signature attests that I am a licensed medical professional and the patient's treating physician authorised to order genetic testing. I attest that the testing is medically necessary and that the test results may impact the medical management of the patient. I have also explained the purpose and limitations of the test(s) to be performed and have obtained the patient/parent/legal guardian's informed consent, to the extent required by applicable law, to allow LifeStrands Genomics (LSG) or any laboratory with which LSG has contracted to perform the test(s) specified herein, including the use & storage of samples for diagnosis, future monitoring, internal quality assurance/operations, and future unspecified research or other purposes.		
Signature	Full Name	Date (DD/MM/YYYY)

Below are recommended specimen requirements to assist in successful genomic profiling.

Acceptable Samples (for Tissue Biopsy)

- **Formalin-fixed paraffin-embedded (FFPE)** specimens, including cut slide specimens, core needle biopsies, fine-needle aspirates, and effusion cytologies (cell blocks).
- Tissue **SHOULD** be FFPE (tissue blocks). Use standard industrial fixation method to preserve nucleic acid integrity.
- **DO NOT** decalcify tissue. Use EDTA if required.

Sample Types	Surface Area & Tumour Purity
 <p>Tissue/Cell Block (preferred) OR Unstained slides of FFPE tissue mounted on uncoated slides* + 1 H&E stained slide (see below for panel-specific requirements)</p> <p><small>*Note: If ordering IHC & methylation test, unstained slides need to be on coated surfaces.</small></p>	 <p>Minimum surface area of 5 x 5 mm² per slide. If the tissue area is smaller, please provide additional slides (as per below). At least 10% tumour purity per slide for Essential/ Enhanced and 20% for Extended/Comprehensive panel testing.</p>

FFPE Slides Requirements (checklist - tick where appropriate)

FFPE on **Uncoated** Slides

- | | | | |
|--|--|--|--|
| <input type="checkbox"/> Essential | <input type="checkbox"/> DNA 68 | <input type="checkbox"/> Extended | <input type="checkbox"/> Comprehensive |
| <input type="checkbox"/> Tissue/Cell Block | <input type="checkbox"/> 10 x 5µm unstained slides | <input type="checkbox"/> 1 H&E stained slide | <input type="checkbox"/> Tissue/Cell Block |
| <input type="checkbox"/> 15 x 5µm unstained slides | <input type="checkbox"/> 1 H&E stained slide | | |

Smaller Tissue Area (< 5 x 5 mm²) Additional 5-10 5µm unstained slides

FFPE on **Coated** Slides

- | | | | | |
|---|---|--|---|--|
| <input type="checkbox"/> Immunohistochemical (IHC) | <input type="checkbox"/> Promoter Methylation | | | |
| <input type="checkbox"/> PD-L1 (SP263) | <input type="checkbox"/> ALK | <input type="checkbox"/> ROS1 | <input type="checkbox"/> MLH1 [#] | <input type="checkbox"/> MGMT |
| <input type="checkbox"/> 4 x 5µm unstained slides/clone | <input type="checkbox"/> Tissue/Cell Block | <input type="checkbox"/> 10 x 5µm unstained slides | <input type="checkbox"/> 10 x 5µm normal tissue slides [#] | <input type="checkbox"/> 1 H&E stained slide |
| <input type="checkbox"/> MMR (MLH, PMS2, MSH2, MSH6) | <input type="checkbox"/> 5 x 5µm unstained slides | | | |

Total no. slides: _____ (uncoated) _____ (coated) **Slides Ref/ID:** _____

Attachments: Copy of the original histology report Additional molecular report (if any)

H&E slide included: Yes No

Normal tissue slides included: Yes No

[#]If available for MLH1 promoter methylation test

FFPE Block Return

Return Address Same as previous Please send to the following:

Test Description

OncoStrands® Essential

A 50-genes targeted NGS panel covering key cancer-related genes for different tumour types, including lung, colon, skin (melanoma), urinary bladder, thyroid, brain, etc. It also covers DNA hotspots from 45 genes, CNVs from 14 genes and fusions from 18 genes.

OncoStrands® DNA 68

A 68-genes hybrid capture DNA NGS panel with coverage of full coding regions of 68 key cancer-related genes (plus TERT promoter region), including BRCA1 & BRCA2. Essential Fusion selection (18 genes) can be ordered in combination with this panel if screening for fusions is clinically important.

OncoStrands® Extended

A 109-genes hybrid capture DNA NGS panel with coverage of full coding regions of 103 genes, including BRCA1 & BRCA2 and many other DNA damage repair genes (plus TERT promoter region). This assay is particularly useful for tumours in the prostate, breast, ovary & fallopian tube, pancreas, biliary tract, uterus and colon. It also provides an accurate MSI score. Essential Fusion selection (18 genes) can be ordered in combination with this panel if screening for fusions is clinically important.

OncoStrands® Comprehensive / Fusion RNA

Based on TSO500 chemistry, this assay offers a comprehensive genomic analysis across 523 genes and targets SNVs, CNVs, fusions (501 genes for compressive fusion conducted separately), splice variants, MSI and TMB. It also provides extensive coverage of NCCN biomarker testing guidelines, genes associated with FDA-approved targeted therapies and clinical trials matching for a variety of tumours.

Immunohistochemical (IHC) & Promoter Methylation Tests

Supplementary tests as add-ons to selected OncoStrands® panels to assist in better treatment decisions and predict outcome response to therapy.

For LifeStrands Laboratory Use ONLY

Reception Date	Reception Time	Received By
Sample Type	Sample ID	
Project/Clinical Trial No.	Remarks (if any)	